Revance Therapeutics Begins BELMONT Phase 2 Trial Of Injectable RT002

(RTTNews) - Revance Therapeutics, Inc. (RVNC) said it has initiated the BELMONT trial, a Phase 2 trial to evaluate the safety and efficacy and duration of the effect of RT002, a Botulinum Toxin Type A for injection, to treat Glabellar Lines, more commonly known as frown lines.

RT002, which incorporates Revance's patented TransMTS delivery technology, is an investigational product designed to offer more targeted delivery of botulinum toxin to intended treatment sites with reduced spread beyond the site of local injection.

Last April, Revance reported the results of a Phase1/2 study which showed median duration of 29.4 weeks, that exceeded the labeled duration of currently marketed botulinum toxin products for the treatment of glabellar lines.

The Belmont trial is a Phase 2, randomized, double-blind, dose ranging, active and placebo controlled, multi-center study that will evaluate the safety, efficacy and duration of three doses of RT002, the labeled dose of the current market leader Botox cosmetic, and a placebo control.